Literature DB >> 23498159

Transsphenoidal microsurgical results of female patients with prolactinomas.

Hidetoshi Ikeda1, Kazuo Watanabe, Teiji Tominaga, Takashi Yoshimoto.   

Abstract

OBJECTIVE: We investigated surgical cure rate and surgical complications of patients with macroprolactinomas who desired pregnancy to evaluate the efficacy of transsphenoidal surgery.
METHODS: Surgical cure rate was investigated in 138 female patients who were under 40 years old.
RESULTS: We found a significant correlation between serum prolactin levels and adenoma volume (r=0.004; p<0.0001), adenoma volume and age (r=-0.213; p<0.03), and proliferative index of the adenoma and age (r=-0.15; p<0.007). Seventy-seven out of 81 patients with enclosed macroadenoma were considered cured, and therefore the overall surgical cure rate was 95%. However, during long-term follow-up, recurrence of adenomas with hyperprolactinemia was seen in 5 out of 81 patients (6%), and the long-term cure rate in patients with enclosed macroadenomas was 89%. Adenomas that did not invade the cavernous sinus showed a significantly higher surgical curability and lower serum prolactin levels, and a smaller size than those adenomas that invaded the cavernous sinus.
CONCLUSIONS: The long-term surgical cure rate was found to be 89% and this success rate far surpasses the complication rate of 39% during pregnancy by dopamine agonist therapy. Thus, transsphenoidal surgery should be considered as a first-line treatment for female patients who desire pregnancy.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cabergoline; Macroadenoma; Pregnancy; Prolactinoma; Transsphenoidal surgery

Mesh:

Substances:

Year:  2013        PMID: 23498159     DOI: 10.1016/j.clineuro.2013.02.016

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  13 in total

Review 1.  The experience with transsphenoidal surgery and its importance to outcomes.

Authors:  Jürgen Honegger; Florian Grimm
Journal:  Pituitary       Date:  2018-10       Impact factor: 4.107

Review 2.  Surgery for prolactinomas: a better choice?

Authors:  Jürgen Honegger; Isabella Nasi-Kordhishti; Nuran Aboutaha; Sabrina Giese
Journal:  Pituitary       Date:  2020-02       Impact factor: 4.107

3.  Extra-Pseudocapsular Transsphenoidal Surgery for Microprolactinoma in Women.

Authors:  Juan Chen; Xiang Guo; Zhuangzhuang Miao; Zhuo Zhang; Shengwen Liu; Xueyan Wan; Kai Shu; Yan Yang; Ting Lei
Journal:  J Clin Med       Date:  2022-07-05       Impact factor: 4.964

Review 4.  Management of hormone-secreting pituitary adenomas.

Authors:  Gautam U Mehta; Russell R Lonser
Journal:  Neuro Oncol       Date:  2017-06-01       Impact factor: 12.300

5.  Long-term follow-up of female prolactinoma patients at child-bearing age after transsphenoidal surgery.

Authors:  Na Yi; Lijin Ji; Qi Zhang; Shuo Zhang; Xiaoxia Liu; Xuefei Shou; Bin Lu
Journal:  Endocrine       Date:  2018-06-22       Impact factor: 3.633

6.  Diagnostic pitfalls of hyperprolactinemia: the importance of sequential pituitary imaging.

Authors:  Tomohiro Kawaguchi; Yoshikazu Ogawa; Teiji Tominaga
Journal:  BMC Res Notes       Date:  2014-08-20

7.  The Chance of Permanent Cure for Micro- and Macroprolactinomas, Medication or Surgery? A Systematic Review and Meta-Analysis.

Authors:  Qianquan Ma; Jun Su; Ying Li; Jiaxing Wang; Wenyong Long; Mei Luo; Qing Liu
Journal:  Front Endocrinol (Lausanne)       Date:  2018-10-25       Impact factor: 5.555

8.  Italian Association of Clinical Endocrinologists (AME) and International Chapter of Clinical Endocrinology (ICCE). Position statement for clinical practice: prolactin-secreting tumors.

Authors:  Renato Cozzi; Maria Rosaria Ambrosio; Roberto Attanasio; Claudia Battista; Alessandro Bozzao; Marco Caputo; Enrica Ciccarelli; Laura De Marinis; Ernesto De Menis; Marco Faustini Fustini; Franco Grimaldi; Andrea Lania; Giovanni Lasio; Francesco Logoluso; Marco Losa; Pietro Maffei; Davide Milani; Maurizio Poggi; Michele Zini; Laurence Katznelson; Anton Luger; Catalina Poiana
Journal:  Eur J Endocrinol       Date:  2022-02-03       Impact factor: 6.664

9.  Surgery is a safe, effective first-line treatment modality for noninvasive prolactinomas.

Authors:  Ji Yong Park; Wonsuk Choi; A Ram Hong; Jee Hee Yoon; Hee Kyung Kim; Woo-Youl Jang; Shin Jung; Ho-Cheol Kang
Journal:  Pituitary       Date:  2021-06-29       Impact factor: 4.107

10.  Prolactinomas: Prognostic Factors of Early Remission After Transsphenoidal Surgery.

Authors:  Grzegorz Zielinski; Marcin Ozdarski; Maria Maksymowicz; Katarzyna Szamotulska; Przemysław Witek
Journal:  Front Endocrinol (Lausanne)       Date:  2020-07-07       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.